Michael J Satlin1,2, Liang Chen3,4, Claire Douglass1,5, Michael Hovan1,6, Emily Davidson1,7, Rosemary Soave1, Marisa La Spina8, Alexandra Gomez-Arteaga9, Koen van Besien9, Sebastian Mayer9, Adrienne Phillips9, Jing-Mei Hsu9, Rianna Malherbe10, Catherine B Small1, Stephen G Jenkins1,2, Lars F Westblade1,2, Barry N Kreiswirth3,4, Thomas J Walsh1. 1. Transplantation-Oncology Infectious Diseases Program, Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, New York, USA. 2. Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York, USA. 3. Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA. 4. Department of Medical Sciences, Hackensack Meridian School of Medicine, Nutley, New Jersey, USA. 5. DeSales University Physician Assistant Program, Center Valley, Pennsylvania, USA. 6. Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA. 7. Cooper Medical School of Rowan University, Camden, New Jersey, USA. 8. NewYork-Presbyterian Hospital/Weill Cornell Medical Center, New York, New York, USA. 9. Department of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, New York, USA. 10. Hardy Diagnostics, Santa Maria, California, USA.
Abstract
BACKGROUND: Levofloxacin prophylaxis is recommended to prevent gram-negative bloodstream infections (BSIs) in patients with prolonged chemotherapy-induced neutropenia. However, increasing fluoroquinolone resistance may decrease the effectiveness of this approach. METHODS: We assessed the prevalence of colonization with fluoroquinolone-resistant Enterobacterales (FQRE) among patients admitted for hematopoietic cell transplantation (HCT) from November 2016 to August 2019 and compared the risk of gram-negative BSI between FQRE-colonized and noncolonized patients. All patients received levofloxacin prophylaxis during neutropenia. Stool samples were collected upon admission for HCT and weekly thereafter until recovery from neutropenia, and underwent selective culture for FQRE. All isolates were identified and underwent antimicrobial susceptibility testing by broth microdilution. FQRE isolates also underwent whole-genome sequencing. RESULTS: Fifty-four of 234 (23%) patients were colonized with FQRE prior to HCT, including 30 of 119 (25%) allogeneic and 24 of 115 (21%) autologous HCT recipients. Recent antibacterial use was associated with FQRE colonization (P = .048). Ninety-one percent of colonizing FQRE isolates were Escherichia coli and 29% produced extended-spectrum β-lactamases. Seventeen (31%) FQRE-colonized patients developed gram-negative BSI despite levofloxacin prophylaxis, compared to only 2 of 180 (1.1%) patients who were not colonized with FQRE on admission (P < .001). Of the 17 gram-negative BSIs in FQRE-colonized patients, 15 (88%) were caused by FQRE isolates that were genetically identical to the colonizing strain. CONCLUSIONS: Nearly one-third of HCT recipients with pretransplant FQRE colonization developed gram-negative BSI while receiving levofloxacin prophylaxis, and infections were typically caused by their colonizing strains. In contrast, levofloxacin prophylaxis was highly effective in patients not initially colonized with FQRE.
BACKGROUND: Levofloxacin prophylaxis is recommended to prevent gram-negative bloodstream infections (BSIs) in patients with prolonged chemotherapy-induced neutropenia. However, increasing fluoroquinolone resistance may decrease the effectiveness of this approach. METHODS: We assessed the prevalence of colonization with fluoroquinolone-resistant Enterobacterales (FQRE) among patients admitted for hematopoietic cell transplantation (HCT) from November 2016 to August 2019 and compared the risk of gram-negative BSI between FQRE-colonized and noncolonized patients. All patients received levofloxacin prophylaxis during neutropenia. Stool samples were collected upon admission for HCT and weekly thereafter until recovery from neutropenia, and underwent selective culture for FQRE. All isolates were identified and underwent antimicrobial susceptibility testing by broth microdilution. FQRE isolates also underwent whole-genome sequencing. RESULTS: Fifty-four of 234 (23%) patients were colonized with FQRE prior to HCT, including 30 of 119 (25%) allogeneic and 24 of 115 (21%) autologous HCT recipients. Recent antibacterial use was associated with FQRE colonization (P = .048). Ninety-one percent of colonizing FQRE isolates were Escherichia coli and 29% produced extended-spectrum β-lactamases. Seventeen (31%) FQRE-colonized patients developed gram-negative BSI despite levofloxacin prophylaxis, compared to only 2 of 180 (1.1%) patients who were not colonized with FQRE on admission (P < .001). Of the 17 gram-negative BSIs in FQRE-colonized patients, 15 (88%) were caused by FQRE isolates that were genetically identical to the colonizing strain. CONCLUSIONS: Nearly one-third of HCT recipients with pretransplant FQRE colonization developed gram-negative BSI while receiving levofloxacin prophylaxis, and infections were typically caused by their colonizing strains. In contrast, levofloxacin prophylaxis was highly effective in patients not initially colonized with FQRE.
Authors: Anton Bankevich; Sergey Nurk; Dmitry Antipov; Alexey A Gurevich; Mikhail Dvorkin; Alexander S Kulikov; Valery M Lesin; Sergey I Nikolenko; Son Pham; Andrey D Prjibelski; Alexey V Pyshkin; Alexander V Sirotkin; Nikolay Vyahhi; Glenn Tesler; Max A Alekseyev; Pavel A Pevzner Journal: J Comput Biol Date: 2012-04-16 Impact factor: 1.479
Authors: L Clifford McDonald; George E Killgore; Angela Thompson; Robert C Owens; Sophia V Kazakova; Susan P Sambol; Stuart Johnson; Dale N Gerding Journal: N Engl J Med Date: 2005-12-01 Impact factor: 91.245
Authors: Koen Van Besien; Lizamarie Bachier-Rodriguez; Michael Satlin; Maxwell A Brown; Usama Gergis; Danielle Guarneri; Jingmei Hsu; Adrienne A Phillips; Sebastian A Mayer; Amrita D Singh; Rosemary Soave; Adriana Rossi; Catherine B Small; Thomas J Walsh; Hanna Rennert; Tsiporah B Shore Journal: Leuk Lymphoma Date: 2019-02-10
Authors: C Gudiol; M Bodro; A Simonetti; F Tubau; E González-Barca; M Cisnal; E Domingo-Domenech; L Jiménez; J Carratalà Journal: Clin Microbiol Infect Date: 2012-04-24 Impact factor: 8.067
Authors: Guillermo V Sanchez; Ahmed Babiker; Ronald N Master; Tony Luu; Anisha Mathur; Jose Bordon Journal: Antimicrob Agents Chemother Date: 2016-04-22 Impact factor: 5.191
Authors: J Klastersky; L Ameye; J Maertens; A Georgala; F Muanza; M Aoun; A Ferrant; B Rapoport; K Rolston; M Paesmans Journal: Int J Antimicrob Agents Date: 2007-08-08 Impact factor: 5.283
Authors: Jeffrey M Kubiak; Michael Hovan; Emily Davidson; Claire Douglass; Kevin Burgos; Thomas J Walsh; Lars F Westblade; Michael J Satlin Journal: J Clin Microbiol Date: 2022-06-13 Impact factor: 11.677
Authors: Michael J Satlin; Liang Chen; Claire Douglass; Michael Hovan; Emily Davidson; Rosemary Soave; Marisa La Spina; Alexandra Gomez-Arteaga; Koen van Besien; Sebastian Mayer; Adrienne Phillips; Jing Mei Hsu; Rianna Malherbe; Catherine B Small; Stephen G Jenkins; Lars F Westblade; Barry N Kreiswirth; Thomas J Walsh Journal: Clin Infect Dis Date: 2022-08-24 Impact factor: 20.999
Authors: Jason N Barreto; Samuel L Aitken; Elizabeth M Krantz; Jerod L Nagel; Sanjeet S Dadwal; Susan K Seo; Catherine Liu Journal: Open Forum Infect Dis Date: 2022-02-04 Impact factor: 4.423
Authors: Louise Caldwell; Anjaneya Bapat; Lydia N Drumright; Jonathan Lambourne; Fergus G Jimenez-England; James Aries; Lydia Eccersley; Simon Hallam; Silvia Montoto; Heather Oakervee; John Riches; Samir G Agrawal Journal: Clin Infect Dis Date: 2022-08-24 Impact factor: 20.999